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The data of this contemporary cohort of patients do not
support the use of one shunt type over the other at the
time of the S1R as it relates to ability to proceed to Fontan
completion. Overall survival between shunt types remains
similar through Fontan completion; however, timing of
death and morbidity are different. There may be a survival
advantage early in the palliation period for patients with
RV-PA conduits, but this seems to diminish over time
with continued attrition with death and transplantation after
S2R. In addition, ventricular dysfunction and AVVR con-
tinue to be significant in those patients with RV-PA conduits
at the time of Fontan completion. This may contribute signif-
icantly to longer-term outcomes. As such, this limited study
group, with the inherent biases to this type of retrospective
study and the relatively short follow-up time period, empha-
sizes the need for longitudinal follow-up in a randomized,
controlled trial, such as the Single Ventricle Reconstruction
trial, which is ongoing at the current time.18
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Dr Christian Pizarro (Wilmington, Del). I congratulate Dr
Ballweg and colleagues on a timely study comparing the outcomes
of patients who underwent Fontan completion after receiving alter-
native sources of pulmonary blood flow at the time of their Nor-
wood procedure. While the pediatric cardiac surgical community
awaits the results of the Single Ventricle Reconstruction trial, these
data provide important information about the impact of each shunt
on the candidacy of these patients to undergo a Fontan procedure
and their operative results and midterm outcome.
The authors conclude that there is no evidence to support the use
of one shunt over the other; nevertheless, each group presented
a different pattern on the timing of death and morbidity. Although
there were more interstage deaths in the mBTS group, when using
a composite end point of death or transplantation, this difference is
neutralized by the fact that 3 patients in the RV-PA group under-
went transplantation after their second stage.
My first question, based on these different patterns of attrition, is
did you identify any specific subgroup of patients who would ben-
efit the most with one specific type of shunt?
Dr Ballweg.No, we did not. We haven’t looked back at the data
and teased out if patients with aortic atresia, those with mitral and
aortic atresia, or the group that some people have reported as higher
risk (ie, mitral stenosis and aortic atresia) would benefit from one
shunt type or the other at this point.
Dr Pizarro. Thank you, considering the difficulty related to the
objective evaluation of right ventricular function, the data pre-
sented show a substantially higher incidence of moderate to severe
right ventricular systolic dysfunction in the RV-PA shunt group,
a finding that has not consistently been reported in other series, par-
ticularly the one that you have mentioned. A review of our own ex-
perience, comparing the outcome of shunt types 3 years after the
Fontan, presented at the Society of Thoracic Surgeons last year,
did not detect any differences in systolic function; however, the in-
cidence and duration of pleural effusions showed a tight correlation
with a history of balloon intervention for recoarctation.
Have you had the opportunity to assess and compare the dia-
stolic properties of these ventricles, and have you observed a similar
phenomenon?
Dr Ballweg. I’ll answer the second part first. In regard to the data
you presented with coarctation and pleural effusions, there were in-
terventions on arch obstruction in these patients, but it was mainly
after Fontan. We have had some patients who also had pre-Fontan
arch obstruction that was relieved, and those patients did not have
increased duration or incidence of pleural effusion. Those data arerdiovascular Surgery c Volume 140, Number 3 543
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Dnot discussed in this article but will be presented in June at the
Western Thoracic Surgical Association meeting.
In regard to your first question, I’m not sure we have a good
method of evaluating diastolic dysfunction, quite honestly. I think
the data showing that the end-diastolic pressure and left atrial pres-
sure are increased are certainly markers that the diastolic function
of the ventricles may be worse for those with an RV-PA conduit
at stage 1.
Dr Pizarro. As longer follow-up is available, the issues of late
failure and need for transplantation becomematters of special inter-
est. TheMichigan group and others have shown that the outcome of
patients with tricuspid valve regurgitation after the Norwood is
closely related to the degree of ventricular dysfunction; therefore,
attempts to correct the tricuspid regurgitation should be undertaken
early. Given the fact that 40% of the patients in the RV-PA shunt
group had important tricuspid regurgitation, could you tell us
how these patients were managed? Did they undergo any attempt
at tricuspid valve repair before or at the time of Fontan, or have
you developed a protocol to address this important issue?
Dr Ballweg. In our previous discussion and publication at stage
2, we had 10 patients who had undergone tricuspid valvuloplasty, 4
were in the mBTS group and 6 were in the RV-PA conduit group.
Unfortunately, I don’t have the specific data on howmany tricus-
pid valvuloplasties were done at the time of the Fontan. I can tell
you of only one that I can recall. And in discussing this with other
people who are here at the meeting with me, it’s rare for us to inter-
vene on tricuspid regurgitation at the time of Fontan. It has to be
extremely severe; however, you want to define that, and certainly
it’s not the norm. So although we had a large percentage of patients
with tricuspid regurgitation by echo definition of multiple re-
viewers, we did not intervene.
As far as management, I think there is a certain camp that tends
to afterload reduce patients with AVVR more aggressively than
others. We do not have a standard protocol, but I think people
are aware that oftentimes afterload reduction may be helpful.
Dr Pizarro.We learned from your previous report on this cohort
of patients that those in the RV-PA group were younger and had
lower arterial saturations at stage 2. Did you observe any difference
in the degree of systemic to pulmonary collaterals present in these
patients before Fontan completion, and were there any differences
in the interventions undertaken?
Dr Ballweg. That wasn’t the objective of our study, and we
didn’t look for it. I don’t have those data to present today.
Dr Emile Bacha (Boston, Mass). I wonder if you’re not measur-
ing 2 different groups of patients. I may havemissed it in the presen-
tation. You probably know that tomorrow we’re presenting out of
Boston a similar series of patients with a bit longer follow-up, and
we found the exact opposite in terms of tricuspid regurgitation rates.544 The Journal of Thoracic and Cardiovascular SurgNow, you showed that approximately two thirds of your patients
had HLHS; the rest had single left ventricles (LVs) and so forth.
Those are patients in whom we would tend to perform mBTS.
Those are patients who tend to do much better in terms of AVVR
and ventricular function. So by comparing these 2 groups, I’m
assuming that you have more single LVs in the mBTS group.
I may be wrong, but that’s my assumption, and I wonder if you
would repeat this analysis with only patients with HLHS.
Dr Ballweg. There were 9 patients with single LVs, and they are
all in the mBTS group. Certainly we could exclude them and redo
the analysis just with HLHS and variants. The variants were the
more common things we see in such an unbalanced canal.
Dr Bacha. I would encourage you to do that because it would be
interesting to see what you find.
Dr Shunji Sano (Okayama City, Japan). The LV dysfunction
and tricuspid regurgitation are concerns for the RV-PA shunt.
But I think the LV dysfunction and tricuspid regurgitation can be
avoided mainly in 2 ways. One is the LV incision. We changed
the technique from excising the LV, the muscle, from the scissors
of knife to punch out the muscle, because it’s more accurate and
the damage to the LV is minimal, rather than the cutting knife
with scissors.
The second one is that the volume overload is also avoided by
putting a clip to the graft to control the saturation. When the oper-
ation is finished, we keep the saturation between 80% and 85%with
a clip, mostly to a 5-mm graft, because our patient population is
smaller than yours. So the volume overload could be controlled.
Then afterward, when the patients grow up, the cardiologists do
balloon dilate and remove the clip so that we can wait a little
more because the average body weight at Fontan is only 10 kg.
So there are 2 ways we can somehow control or manage or mini-
mize the LV dysfunction and tricuspid regurgitation.
What is your technique of LV incision? What size graft do you
use in an RV-PA shunt? When you finish the RV-PA shunt, how
much is the saturation, and can you try to control the saturation
to control the volume overload?
Dr Ballweg.We do not use the punch technique. So if you have
seen a change in ventricular dysfunction and AVVR, it may be
a better option. We do not do anything to control the pulmonary
blood flow through the Sano conduit at the time the operation is
completed. I believe the majority of our conduits are 5 mm as
well. Our saturations are generally in the mid to high 80s when
patients leave the operating room.
Dr Frank Hanley (Stanford, Calif). Was there any correlation
between the reduced right ventricular function by ejection fraction
determined by echocardiography and the right ventricular end-dia-
stolic pressure at the pre-Fontan catheterization?
Dr Ballweg. No, there was not.ery c September 2010
